SMMT
Summit Therapeutics Inc. NASDAQ Listed Mar 5, 2015$13.75
-2.27%
vs $14.07
Mkt Cap $10.3B
52w Low $13.05
4.3% of range
52w High $29.32
50d MA $18.09
200d MA $17.96
P/E (TTM)
-9.6x
EV/EBITDA
—
P/B
15.6x
Debt/Equity
0.0x
ROE
-163.9%
P/FCF
-31.8x
RSI (14)
23.30
ATR (14)
$0.98
Beta
-1.37
50d MA
$18.09
200d MA
$17.96
Avg Volume
5.8M
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
One Broadway · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.27 | -0.24 | +10.8% | 21.46 | -25.3% | -24.9% | +5.4% | +3.3% | +1.8% | -3.9% | — |
| Feb 23, 2026 | AMC | -0.10 | -0.29 | -182.6% | 16.09 | -1.9% | +0.2% | -2.7% | +0.8% | +5.0% | -2.4% | — |
| Oct 20, 2025 | AMC | -0.18 | -0.31 | -76.3% | 20.04 | -0.2% | -6.5% | +2.2% | -2.1% | +2.8% | +0.9% | — |
| Aug 11, 2025 | AMC | -0.09 | -0.76 | -736.9% | 28.25 | -4.2% | -9.1% | +4.6% | -1.6% | +0.9% | -1.5% | — |
| May 1, 2025 | AMC | -0.09 | -0.09 | +3.2% | 24.67 | +5.1% | +13.1% | +0.4% | -13.6% | +0.4% | +1.5% | — |
| Feb 24, 2025 | AMC | -0.08 | -0.08 | +2.2% | 18.84 | +1.9% | -3.9% | +1.0% | +1.0% | +11.9% | -7.5% | — |
| Oct 30, 2024 | AMC | -0.07 | -0.08 | -14.3% | 18.65 | +0.5% | -0.3% | +2.2% | +5.1% | +2.2% | +2.5% | — |
| Aug 6, 2024 | AMC | -0.06 | -0.05 | +16.7% | 9.54 | -0.4% | -1.5% | +8.9% | +5.3% | +1.9% | +2.5% | — |
| May 1, 2024 | AMC | -0.06 | -0.06 | +0.0% | 4.70 | -0.4% | -13.6% | +8.1% | +1.8% | +18.8% | -6.6% | — |
| Feb 20, 2024 | AMC | — | -0.04 | — | 3.74 | +0.0% | +9.9% | +4.6% | +7.9% | -3.9% | -1.3% | — |
| Nov 7, 2023 | AMC | — | -0.03 | — | 1.92 | -0.3% | -4.7% | -3.8% | +8.5% | -3.4% | +7.1% | — |
| Aug 9, 2023 | AMC | — | -0.02 | — | 1.94 | +0.5% | -8.2% | -3.4% | +15.1% | -3.0% | -7.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 22 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $17.47 | $16.48 | -5.7% | -4.9% | +2.3% | +2.1% | +0.3% | +0.7% |
| May 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $21.46 | $16.02 | -25.3% | -24.9% | +5.4% | +3.3% | +1.8% | -3.9% |
| Apr 8 | Stifel | Maintains | Buy → Buy | — | $19.22 | $19.99 | +4.0% | -2.1% | +2.7% | +1.9% | +1.8% | +4.1% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $16.12 | $16.07 | -0.3% | +0.4% | -2.0% | -1.6% | +0.8% | -1.3% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.09 | $15.78 | -1.9% | +0.2% | -2.7% | +0.8% | +5.0% | -2.4% |
| Feb 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.48 | $14.21 | -1.9% | -2.9% | +3.8% | -1.2% | -4.0% | +8.2% |
| Jan 30 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.40 | $15.20 | -1.3% | -6.0% | -2.9% | +3.8% | -1.2% | -4.0% |
| Dec 17 | Barclays | Upgrade | Underweight → Equal Weight | — | $17.23 | $17.65 | +2.4% | -1.3% | +0.2% | +4.6% | +1.9% | -0.2% |
| Oct 22 | Guggenheim | Maintains | Buy → Buy | — | $18.74 | $19.58 | +4.5% | +2.2% | -2.1% | +2.8% | +0.9% | -1.2% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.04 | $19.99 | -0.2% | -6.5% | +2.2% | -2.1% | +2.8% | +0.9% |
| Oct 21 | Barclays | Maintains | Underweight → Underweight | — | $20.04 | $19.99 | -0.2% | -6.5% | +2.2% | -2.1% | +2.8% | +0.9% |
| Oct 20 | Citigroup | Maintains | Buy → Buy | — | $20.99 | $18.85 | -10.2% | -4.5% | -6.5% | +2.2% | -2.1% | +2.8% |
| Oct 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $20.99 | $18.85 | -10.2% | -4.5% | -6.5% | +2.2% | -2.1% | +2.8% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.94 | $18.99 | +0.3% | -4.3% | -0.2% | +6.3% | -1.8% | +1.1% |
| Sep 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $25.98 | $21.53 | -17.1% | -25.1% | -3.2% | -6.5% | +5.6% | +1.8% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.98 | $21.53 | -17.1% | -25.1% | -3.2% | -6.5% | +5.6% | +1.8% |
| Sep 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.84 | $23.82 | -0.1% | -1.3% | +1.2% | +9.2% | -25.1% | -3.2% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.70 | $23.13 | -2.4% | +0.6% | -1.3% | +1.2% | +9.2% | -25.1% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.98 | $26.23 | -2.8% | -8.0% | -1.6% | -2.9% | +0.6% | -1.3% |
| Aug 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $26.29 | $25.63 | -2.5% | -3.6% | +2.1% | +0.5% | +0.7% | +0.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.45 | $26.49 | +0.2% | +0.9% | -1.5% | -3.6% | +2.1% | +0.5% |
| Aug 12 | Evercore ISI | Maintains | Outperform → Outperform | — | $28.25 | $27.06 | -4.2% | -9.1% | +4.6% | -1.6% | +0.9% | -1.5% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.28 | $21.28 | +0.0% | -0.4% | +6.7% | +8.5% | -7.9% | +1.7% |
| Jun 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.22 | $18.81 | +3.2% | -2.7% | +16.3% | -5.1% | +0.9% | +4.4% |
| May 2 | Goldman Sachs | Maintains | Buy → Buy | — | $24.67 | $25.93 | +5.1% | +13.1% | +0.4% | -13.6% | +0.4% | +1.5% |
| Apr 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.47 | $24.38 | +3.9% | +2.7% | -2.0% | +2.1% | +2.3% | +13.1% |
| Apr 25 | Jefferies | Maintains | Buy → Buy | — | $36.70 | $34.48 | -6.0% | -36.0% | +2.7% | -2.0% | +2.1% | +2.3% |
| Apr 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.35 | $29.95 | +9.5% | +21.5% | +10.4% | -36.0% | +2.7% | -2.0% |
| Mar 26 | Citigroup | Upgrade | Neutral → Buy | — | $20.24 | $21.45 | +6.0% | -1.7% | +3.6% | -1.4% | -5.1% | -2.5% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.84 | $19.20 | +1.9% | -3.9% | +1.0% | +1.0% | +11.9% | -7.5% |
| Feb 25 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $18.84 | $19.20 | +1.9% | -3.9% | +1.0% | +1.0% | +11.9% | -7.5% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.03 | $19.25 | +1.2% | +16.1% | +6.4% | +4.8% | -3.6% | -1.0% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.31 | $18.36 | +0.3% | +3.7% | +5.4% | -6.9% | -1.1% | +3.1% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.65 | $18.75 | +0.5% | -0.3% | +2.2% | +5.1% | +2.2% | +2.5% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.31 | $12.40 | +0.7% | +8.4% | +1.3% | -3.3% | +1.3% | +1.7% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.12 | $11.45 | +3.0% | +6.7% | -2.3% | +5.6% | +0.5% | +8.4% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.25 | $11.57 | +2.8% | -1.2% | +6.7% | -2.3% | +5.6% | +0.5% |
| Jun 3 | Stifel | Maintains | Buy → Buy | — | $8.69 | $9.84 | +13.2% | +1.7% | -17.3% | +10.0% | +1.1% | -5.0% |
| May 31 | Citigroup | Maintains | Buy → Buy | — | $10.92 | $9.07 | -16.9% | -20.4% | +1.7% | -17.3% | +10.0% | +1.1% |
| Nov 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.21 | $4.20 | -0.2% | +1.7% | +1.4% | +3.7% | +6.4% | -1.7% |
| Nov 25 | SunTrust Robinson Humphrey | Downgrade | Buy → Hold | — | $4.21 | $4.20 | -0.2% | +1.7% | +1.4% | +3.7% | +6.4% | -1.7% |
| Nov 25 | Janney Capital | Downgrade | Buy → Neutral | — | $4.21 | $4.20 | -0.2% | +1.7% | +1.4% | +3.7% | +6.4% | -1.7% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.21 | $4.20 | -0.2% | +1.7% | +1.4% | +3.7% | +6.4% | -1.7% |
| Nov 18 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $4.58 | $4.32 | -5.7% | -1.3% | +0.2% | -2.9% | +0.0% | -4.3% |
| Mar 19 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.75 | $2.71 | -1.5% | -2.9% | -12.4% | -12.0% | +2.9% | +11.8% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.71 | -1.5% | -2.9% | -12.4% | -12.0% | +2.9% | +11.8% |
| Jun 28 | Janney Capital | Downgrade | Buy → Neutral | — | $2.55 | $2.52 | -1.2% | -6.7% | +2.9% | +1.2% | +4.8% | -5.0% |
| Jun 28 | Janney Montgomery Scott | Downgrade | Buy → Neutral | — | $2.55 | $2.52 | -1.2% | -6.7% | +2.9% | +1.2% | +4.8% | -5.0% |
| Jun 27 | SunTrust Robinson Humphrey | Downgrade | Buy → Hold | — | $12.65 | $2.90 | -77.1% | -79.8% | -6.7% | +2.9% | +1.2% | +4.8% |
| May 2 | Janney Capital | Maintains | Buy → Buy | — | $13.42 | $13.50 | +0.6% | +2.5% | -0.1% | -0.1% | +0.2% | -0.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | DUGGAN ROBERT WDir/Off | Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | 573,883,879 | +0.86% | — |
| Jun 12, 2026 | Zanganeh MahkamDir/Off | Co-Chief Executive Officer | Buy | 3,810,000 | $13.12 | $50.0M | 573,883,879 | +0.86% | — |
| Jun 4, 2026 | DUGGAN ROBERT WDir/Off | Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | 25,824,474 | -0.47% | +0.23% |
| Jun 4, 2026 | Zanganeh MahkamDir/Off | Co-Chief Executive Officer | Buy | 100,000 | $14.60 | $1.5M | 25,824,474 | -0.47% | +0.23% |
| Jun 4, 2026 | Soni Manmeet SinghDir/Off | COO and CFO | Buy | 25,000 | $14.46 | $362K | 3,098,603 | -0.47% | +0.23% |
8-K
Summit Therapeutics Inc. -- 8-K Filing
Jun 12
8-K · 7.01
! Medium
Summit Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 11
8-K · 8.01
!! High
Summit Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Jun 3
8-K · 8.01
!! High
Summit Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Akeso's Phase III HARMONi-6 trial for AK112-306 produced results published on May 31, 2026, which Summit Therapeutics announced via press release, though specific efficacy or safety outcomes require reviewing the full release details.
Jun 1
8-K · 7.01
! Medium
Summit Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Summit Therapeutics will present fourth-quarter and full-year 2025 financial results on February 23, 2026, providing investors with operational updates via earnings call slides.
Feb 23
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 10,853,199 | $206M | Reduced | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 5,711,802 | $108M | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 5,233,252 | $99M | New | Mar 2026 |
| 4 | Ubs Group Ag | 3,680,315 | $70M | Added | Mar 2026 |
| 5 | D.e. Shaw & Co | 2,242,229 | $43M | Added | Mar 2026 |
| 6 | Morgan Stanley | 1,853,158 | $32M | Reduced | Dec 2025 |
| 7 | Pictet Asset Management Holding Sa | 1,383,775 | $24M | Reduced | Dec 2025 |
| 8 | Apeiron Capital Ltd | 1,309,241 | $23M | — | Dec 2025 |
| 9 | Two Sigma Investments, Lp | 981,185 | $19M | Added | Mar 2026 |
| 10 | Superstring Capital Management Lp | 892,873 | $17M | New | Mar 2026 |
| 11 | Point72 Asset Management | 784,186 | $15M | New | Mar 2026 |
| 12 | Aberdeen Group Plc | 665,364 | $13M | Reduced | Mar 2026 |
| 13 | Susquehanna International Group, Llp | 603,933 | $11M | New | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 598,692 | $11M | Reduced | Mar 2026 |
| 15 | Northern Trust Corp | 581,600 | $11M | Added | Mar 2026 |
| 16 | Invesco Ltd. | 526,103 | $10M | Added | Mar 2026 |
| 17 | Candriam S.c.a. | 540,662 | $9M | Added | Dec 2025 |
| 18 | Marshall Wace, Llp | 475,241 | $9M | New | Mar 2026 |
| 19 | Citadel Advisors Llc | 441,743 | $8M | Reduced | Mar 2026 |
| 20 | Aqr Capital Management Llc | 443,757 | $8M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$10.28B
Enterprise Value
$9.57B
P/E (TTM)
-9.55x
Forward P/E
—
PEG Ratio
-0.03x
P/B
15.60x
P/S
—
P/FCF
-31.77x
EV/EBITDA
—
Shares Out
747.7M
Financials (TTM)
Revenue
$0
Net Income
-$1.08B
EBITDA
-$801.1M
Free Cash Flow
-$323.6M
Op Cash Flow
-$322.9M
EPS Basic
$-1.44
EPS Diluted
$-1.44
EPS Forward
$-1.18
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$751.2M
Total Liab.
$92.3M
Total Equity
$658.9M
Cash
$713.4M
LT Debt
$0
Book Value/Sh
$0.88
Debt/Equity
0.03x
Current Ratio
9.87
Quick Ratio
9.87
Returns & Growth
ROE
-163.9%
ROA
-143.7%
ROIC
-160.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-364.5%
Price Returns
2W
-3.3%
1M
-18.3%
3M
+5.7%
6M
-2.0%
12M
-3.7%
Technicals
52W High
$29.32
52W Low
$13.05
50d MA
$18.09
200d MA
$17.96
RSI (14)
23.30
ATR (14)
$0.98
Beta
-1.37
Avg Volume
5.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$29.33
High
$40.00
Low
$18.00
Median
$30.00
Data updated apr 27, 2026 1:56am
· Source: financialmodelingprep.com